Pantoprazole Sodium NDC 62756-071

NDC codes

FDA NDC Directory

Product NDC (as listed)62756-071Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62756-0071Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62756-071-64	62756007164	30 PACKET in 1 CARTON (62756-071-64) / 1 GRANULE, DELAYED RELEASE in 1 PACKET (62756-071-60)Marketed from Jul 1, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pantoprazole Sodium
Generic name (nonproprietary): pantoprazole sodium
Active ingredients: Pantoprazole sodium — 40 mg/1
Dosage form: Granule, Delayed release
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213725
Marketing start: Jul 1, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 62756-071_d19d65d9-7bab-4a6f-9a79-ed3d32bd83d9SPL ID d19d65d9-7bab-4a6f-9a79-ed3d32bd83d9SPL set ID 38353b9e-63bd-47e8-b7cb-b198d1e901f9RxCUI 763306UNII 6871619Q5XUPC 0362756071643
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462756007164 followed by a unit qualifier and the quantity

Package 62756-0071-64. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 3, 2023.

Indications (excerpt from the label)

Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1) Maintenance of Healing of Erosive Esophagitis (1.2) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome (1.3) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium for delayed-release oral suspension is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and sym…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213725

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213725
Product	Strength	Form · route	Labeler	Product NDC
Pantoprazole Sodium	Pantoprazole sodium 40 mg/1	Granule, Delayed releaseOral	NorthStar RxLLC	72603-317